. Multi-level fibrillar amyloid thresholds of florbetapir F18 PET images from five multi-center studies. Human Amyloid Imaging 2011 Meeting Abstracts. 2011 Jan 15;


Objectives: To characterize quantitative and visual florbetapir F18 positron emission tomography (PET) measurements of fibrillar amyloid-s (As) burden in a large clinical cohort of probable Alzheimer's disease (pAD), mild cognitive impairment (MCI), and older healthy controls (oHC); and to assess percent positivity of those meeting empirically predetermined florbetapir PET criteria associated with an intermediate-to-high likelihood of pathologic AD (pathAD) or having gany Ash pathology above that typically seen in young-low-risk individuals. Materials and

Methods: PET scans and clinical evaluations were analyzed for 210 participants from 5 multicenter studies. Cerebral-to-whole-cerebellar florbetapir standard-uptake-value ratios (SUVRs) were computed in 68 pAD, 60 MCI, and 82 oHCs (.55 years old). A threshold of SUVRs .1.17 was used to reflect pathAD based on separate antemortem PET and postmortem neuropathology data from 19 end-of-life patients; Similarly a threshold of SUVRs >1.08 was used to signify gany Ash as this was the upper limit from a separate set of 46 18-40 year-old APOE4 noncarriers.

Results: The pAD, MCI, and oHC participants differed significantly in mean cortical florbetapir SUVRs (1.39}0.24>1.17}0.27>1.05}0.16; p 40.0>20.7%, p 46.6>28.1%, p 1.03}0.16, p = 0.048).

Conclusions: This analysis supports the ability of florbetapir PET SUVRs to characterize As levels in clinical pAD, MCI, and oHC groups, and in oHC APOE4 carriers and noncarriers, using continuous and dichotomous measures of fibrillar As burden. It introduces criteria to determine whether an image is associated with As of intermediateto- high likelihood of pathologic AD or with gany Ash levels.


Please login to recommend the paper.


No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Miami: HAI Amyloid Imaging Conference Abstracts